Trials Sponsors Conditions Drugs Pricing

Conditions

Chronic Hepatitis B Liver Fibrosis DDI (Drug-Drug Interaction)

Keywords

HydronidoneF351

Outcome Measures

Primary Outcomes (10)

Plasma hydronidone PK parameters of hydronidone capsules : steady-state peak concentration (Cmax,ss);
23 days
Plasma hydronidone PK parametersof hydronidone capsules : Area under the plasma concentration-time curve from time zero to 24 hours at steady state (AUC0-24h,ss)
23 days
Primary PK parameters of plasma of entecavir : AUC0-24h,ss.
23 days
Primary PK parameters of plasma of entecavir : Cmax,ss .
23 days
Primary PK parameters of plasma tenofovir alafenamide (TAF) : AUC0-24h,ss.

Study Arms (4)

Queue 1: Drug-Drug Interaction Study of Hydronidone Capsules and Entecavir

EXPERIMENTAL

Within each cohort, the study flow for enrolled subjects comprises three dosing periods: Period 1 consists of hydronidone capsules administered alone for 5 consecutive days; Period 2 consists of the chronic hepatitis B antiviral agent administered alone for 7 or 10 consecutive days; and Period 3 consists of concomitant administration of hydronidone capsules and the antiviral agent for 5 consecutive days. Subjects may be discharged from the study upon completion of the safety follow-up. hydronidone capsules,90 mg three times daily, under fasting conditions

Drug: Entecavir

Queue 2: Drug-Drug Interaction Study of honyinone capsules and Tenofovir Disoproxil Fumarate;

EXPERIMENTAL

Interventions

EntecavirDrug

0.5 mg, taken orally on an empty stomach, once a day

Queue 1: Drug-Drug Interaction Study of Hydronidone Capsules and Entecavir

Tenofovir Disoproxil Fumarate（TDF）Drug

300 mg, taken orally on an empty stomach, once a day

Queue 2: Drug-Drug Interaction Study of honyinone capsules and Tenofovir Disoproxil Fumarate;

Eligibility Criteria

Age18 Years - 50 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Be fully informed about the trial and demonstrate understanding of its content, procedures, and potential adverse events related to the investigational product; voluntarily provide written informed consent; and be able to comply with all study procedures and complete the study in accordance with the protocol requirements.

Sponsors & Collaborators

Beijing Continent Pharmaceutical Co, Ltd.
Industrylead

Study Sites (1)

Beijing Gaobo Hospital

Beijing, 100000, China

MeSH Terms

Interventions

entecavir

Enrollment

64 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 10, 2025

First Posted

December 22, 2025

Study Start

March 15, 2026

Actual (reported)

You may not qualify if:

Presence of any clinically significant disease or medical history that, in the opinion of the investigator, may interfere with protocol compliance or completion of the study, including but not limited to abnormalities of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematologic system, immune system, psychiatric system, or endocrine/metabolic system.
Positive results for any infectious disease screening tests at screening, including hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus antigen/antibody (HIV Ag/Ab), or Treponema pallidum antibody (TP Ab).
History of drug or food allergies, or known hypersensitivity to the active pharmaceutical ingredients of the investigational medicinal products (hydronidone, entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide) or to any of their excipients.
Participants with rare genetic disorders of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption;
Subjects who have experienced a clinically significant major illness within 3 months prior to screening, or have undergone surgery affecting drug absorption, distribution, metabolism, or excretion (such as gastrointestinal, hepatic, or renal surgery) or other major surgery within this period, or plan to undergo surgery during the study;
Subjects who have donated blood or experienced blood loss ≥400 mL within 3 months prior to dosing, or received blood transfusion or blood products within 4 weeks prior to dosing, or plan to donate blood during the study period;
Subjects who have participated as a participant in any clinical trial and received investigational drug or device treatment within 3 months prior to dosing;
Subjects who have taken any prescription medication, over-the-counter medication, vitamin products, or herbal medicines within 14 days or 5 half-lives (if known) prior to dosing, whichever is longer; or who have taken strong inhibitors or inducers of CYP3A4, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), OATP1B1, OATP1B3, or OAT1/3 within 4 weeks prior to screening; or any drugs known to cause QT/QTc interval prolongation or with a known risk of causing torsades de pointes (TdP) (see Appendix 2); or plan to use any chemical drugs, biological products, traditional Chinese medicines, or natural medicines that the investigator deems inappropriate during the trial period;
Subjects who received vaccination within 4 weeks prior to screening, or plan to receive vaccination during the study period up to 1 month after the last dose; Subjects with a history of drug abuse within the past 5 years, or who used illicit drugs within 3 months prior to screening, or with a positive urine drug abuse screen at baseline;
Subjects who regularly consumed alcohol within 6 months prior to dosing, i.e., more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or who refuse to abstain from alcohol or alcohol-containing products during the trial, or with a positive alcohol breath test at baseline;
Subjects who smoked more than 5 cigarettes daily within 3 months prior to dosing, or who are unable to discontinue use of tobacco products during the trial period;
Subjects with a history of blood-needle phobia/syncope, or unable to tolerate venous indwelling needle puncture;
Subjects with special dietary requirements who cannot follow the standardized diet, or with difficulty swallowing;
Subjects unable to avoid specific foods/diet during the trial period, including dragon fruit, mango, grapefruit or grapefruit-related citrus fruits (e.g., Seville orange, pomelo), star fruit, papaya, pomegranate or products thereof, and/or xanthine-containing diet, caffeine-containing food or beverages, strong tea, etc.;
Subjects who consumed grapefruit or grapefruit-related citrus fruits (e.g., Seville orange, pomelo) or products thereof within 2 weeks prior to dosing, or who consumed specific diet (including dragon fruit, mango and/or xanthine-containing diet, caffeine-containing food or beverages, strong tea, etc.) within 48 hours prior to dosing, or engaged in strenuous exercise, or have other factors that may affect drug absorption, distribution, metabolism, or excretion;
+3 more criteria

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (10)

Study Arms (4)

Queue 1: Drug-Drug Interaction Study of Hydronidone Capsules and Entecavir

Queue 2: Drug-Drug Interaction Study of honyinone capsules and Tenofovir Disoproxil Fumarate;

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Enrollment

Study Design

Study Record Dates

Drug-Drug Interaction Study of Fuzuloprim Capsules with Tenofovir Alafenamide

Queue 4: Drug-Drug Interaction Study of Hydronidone Capsules and Tenofovir Amibufenamide

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (10)

Study Arms (4)

Queue 1: Drug-Drug Interaction Study of Hydronidone Capsules and Entecavir

Queue 2: Drug-Drug Interaction Study of honyinone capsules and Tenofovir Disoproxil Fumarate;

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Enrollment

Study Design

Study Record Dates

Drug-Drug Interaction Study of Fuzuloprim Capsules with Tenofovir Alafenamide

Queue 4: Drug-Drug Interaction Study of Hydronidone Capsules and Tenofovir Amibufenamide

You may not qualify if:

Source record

Locations